Kiniksa(US:KNSA)2025-10-28 11:39Revenue Performance - ARCALYST (rilonacept) Q3 2025 net product revenue reached $180.9 million, reflecting a 61% year-over-year growth[1] - Total revenue for Q3 2025 was $180.9 million, compared to $112.2 million for Q3 2024, indicating significant growth[10] - Total revenue for the three months ended September 30, 2025, was $180.855 million, a 61% increase from $112.214 million in the same period of 2024[22] Income and Expenses - Net income for Q3 2025 was $18.4 million, a turnaround from a net loss of $12.7 million in Q3 2024[10] - Net income for the three months ended September 30, 2025, was $18.435 million, compared to a net loss of $12.693 million in the same period of 2024[22] - Total operating expenses for Q3 2025 were $156.8 million, up from $121.9 million in Q3 2024, including $63.3 million in collaboration expenses[10] - Operating expenses for the three months ended September 30, 2025, totaled $156.834 million, up from $121.872 million in the same period of 2024, reflecting a 28.7% increase[22] Cash and Assets - The cash balance increased by $44.3 million in Q3 2025, totaling $352.1 million, with no debt reported[10] - Cash, cash equivalents, and short-term investments rose to $352.102 million as of September 30, 2025, up from $243.627 million as of December 31, 2024, indicating a 44.7% increase[24] - Total assets as of September 30, 2025, increased to $712.333 million from $580.553 million as of December 31, 2024, representing a 22.7% growth[24] - Total shareholders' equity increased to $535.383 million as of September 30, 2025, compared to $438.436 million as of December 31, 2024, marking a 22.1% rise[24] Research and Development - Research and development expenses for the nine months ended September 30, 2025, were $62.244 million, down from $76.408 million in the same period of 2024, reflecting an 18.6% decrease[22] - KPL-387 has been granted Orphan Drug Designation for the treatment of pericarditis by the FDA[10] - Kiniksa plans to initiate the pivotal portion of the KPL-387 Phase 2/3 clinical trial after data from the dose-focusing portion is expected in the second half of 2026[10] Shareholder Information - The company reported a basic net income per share of $0.25 for the three months ended September 30, 2025, compared to a loss of $0.18 per share in the same period of 2024[22] - The company had a weighted average of 74,714,846 basic ordinary shares outstanding for the three months ended September 30, 2025, compared to 71,726,685 in the same period of 2024[22] Other Financial Metrics - The accumulated deficit as of September 30, 2025, was $476.337 million, an improvement from $521.143 million as of December 31, 2024[24] - Kiniksa's current operating plan is expected to remain cash flow positive on an annual basis[10] - The average total duration of ARCALYST therapy in recurrent pericarditis increased to approximately 32 months, compared to 27 months at the end of 2024[5] - The 2025 expected net product revenue for ARCALYST has been raised to between $670 million and $675 million, up from the previous guidance of $625 million to $640 million[3]